Next report date
Report period
Q1 2024
EPS estimate
−0.54USD
Revenue estimate
—
−2.18USD
−71.58 MUSD
25.32 M
About Enliven Therapeutics, Inc.
Sector
Industry
CEO
Samuel S. Kintz
Website
Headquarters
Boulder
Employees (FY)
46
Founded
2019
FIGI
BBG00CP3BDD4
Enliven Therapeutics, Inc. operates as a clinical stage precision oncology company. It is focused on the discovery and development of next-generation small molecule kinase inhibitors and advancing Enliven's pipeline of precision oncology product candidates. The company was founded by Sam S. Kintz, Joe P. Lyssikatos, and Anish Patel in June 2019 and is headquartered in Boulder, CO.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of ELVN is 17.18 USD — it has increased by 2.38% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Enliven Therapeutics, Inc. stocks are traded under the ticker ELVN.
Enliven Therapeutics, Inc. is going to release the next earnings report on May 9, 2024. Keep track of upcoming events with our Earnings Calendar.
ELVN stock is 8.42% volatile and has beta coefficient of 2.47. Check out the list of the most volatile stocks — is Enliven Therapeutics, Inc. there?
ELVN earnings for the last quarter are −0.51 USD per share, whereas the estimation was −0.47 USD resulting in a −7.94% surprise. The estimated earnings for the next quarter are −0.54 USD per share. See more details about Enliven Therapeutics, Inc. earnings.
Yes, you can track Enliven Therapeutics, Inc. financials in yearly and quarterly reports right on TradingView.
ELVN stock has fallen by 2.77% compared to the previous week, the month change is a 3.37% fall, over the last year Enliven Therapeutics, Inc. has showed a 11.08% decrease.
ELVN net income for the last quarter is −19.37 M USD, while the quarter before that showed −20.77 M USD of net income which accounts for 6.74% change. Track more Enliven Therapeutics, Inc. financial stats to get the full picture.
Today Enliven Therapeutics, Inc. has the market capitalization of 804.12 M, it has decreased by 5.72% over the last week.
No, ELVN doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
Like other stocks, ELVN shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Enliven Therapeutics, Inc. stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 28, 2024, the company has 46.00 employees. See our rating of the largest employees — is Enliven Therapeutics, Inc. on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Enliven Therapeutics, Inc. technincal analysis shows the neutral today, and its 1 week rating is buy. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Enliven Therapeutics, Inc. stock shows the neutral signal. See more of Enliven Therapeutics, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on Enliven Therapeutics, Inc. future price: according to them, ELVN price has a max estimate of 37.00 USD and a min estimate of 32.00 USD. Read a more detailed Enliven Therapeutics, Inc. forecast: see what analysts think of Enliven Therapeutics, Inc. and suggest that you do with its stocks.